ClinicalTrials.gg
RecruitingNCT06717334Updated Oct 9, 2026

A Study of Lung Cancer Screening in People With Unexplained Weight Loss

An observational study in Lung Cancer Screening, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 9, 2026Study contact changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
409
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center — 9 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
3rd of 30
409 · median 78
Started
2024
with 2 others
Observational
30 of 108
3 open now
Primary completion
2027-12
later than 16 of 19 live
Registered
105th of 108
by date

Among the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 3rd largest by planned enrollment of the 30 observational ones that give a count, is one of 3 that started in 2024, is one of 30 observational ones, reaches primary completion later than 16 of the 19 other live ones, and was the 105th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The researchers are doing this study to see if people with unexplained weight loss who have lung cancer screening are more likely to have or develop lung cancer than people without unexplained weight loss. The lung cancer screening will involve use of low-dose computed tomography (LDCT), a CT scan that gives off very low doses of radiation and can make detailed pictures of the lungs to help find tumors. The study researchers will also analyze participants' blood samples to determine if blood testing can be used to help to diagnose lung cancer.

03

Conditions studied

  • Lung Cancer Screening

Browse trials for

Keywords

  • ctDNA analysis
  • Low dose computed tomography (CT)
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Potential research subjects will be identified at MSKCC largely through survivorship clinics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for American Cancer Society lung cancer screening, as follows as per the discretion of the screening team:

    • Age 50-80 years old
    • At least 20-pack year history of smoking
  • Weight loss of 3-10%, defined as UWL, within any timeframe over the past in the 18 months prior to enrollment, that cannot be attributed to an underlying medical condition at the discretion of the enrolling investigator

    • Note that patients who have 3-10% weight may still be enrolled if the enrolling investigator does not conclude that the weight loss can be attributed to the patient's intentional efforts.
    • Documented weight loss can be self-reported or extracted from weights obtained during physician visits. However, if self-reported weight loss is contradicted by weight loss documented in the medical record (e.g. a patients states that (s)he lost 10 lbs in the past 6 months, but a weight documented in the medical record does not support that history), the measured and quantified weight change will be used to ascertain eligibility
  • greater than 1 year, per assessment of the treating clinician.

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant or trying to become pregnant via self-report
  • Prior history of recent CT scan of the chest either through LDCT screening or with a scan of the chest (standard, not LDCT) performed within the past 12 months
  • Prior history of NSCLC

    ○ Note that patients with a history of diagnosis of non-lung cancers are eligible for the study.

  • Currently undergoing or referred for diagnostic evaluation due to clinical suspicion for (e.g., referred to a medical or surgical oncologist, or scheduled for on the basis of a suspicious imaging abnormality).
  • Patients with a germline pathogenic genetic variant who have undergone whole body MRI within the past 12 months
  • Unable to comply with study procedures
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
409 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients undergoing Lung cancer screening

    All patients will undergo prospective LDCT imaging annually. At baseline and Year 1, patients will also undergo biospecimen collection for post-hoc ctDNA analysis.

    Diagnostic Test: Low Dose CT imaging · Other: blood draws · Other: screening questionnaire

Interventions

  • Diagnostic testLow Dose CT imaging

    at baseline and at Year 1.

  • Otherblood draws

    at baseline and at Year 1.

  • Otherscreening questionnaire

    at baseline and at 1 year after registration.

06

What researchers measure

Primary outcomes

  1. The incidence of lung cancer in patients with unexplained weight loss

    Low Dose CT screening

    Time frame: 2 years

07

Study locations

8 of 8 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact212-639-8100
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact212-639-8100
  • Memorial Sloan Kettering Bergen (All Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact212-639-8100
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact212-639-8100
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact212-639-8100
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact212-639-8100
  • Montefiore Health Systems (Montefiore Medical Center)
    The Bronx, New York 10467, United States
    Recruiting
    • Neel Chudgar, MD · Contact718-920-8874
  • Memorial Sloan Kettering Nassau (All Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Alexis Chidi, MD, PhD · Contact212-639-8100
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 36 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Dec 5, 2024
StartActual
Dec 2, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, United States
Show 1 removed
  • Memorial Sloan Kettering Westchester (All Protocol Activities) · East White Plains, United States
Oct 9, 2026
Contact
Study contact changed: x•••@mskcc.org · •••6863→c•••@mskcc.org · •••8100. See the current contact
Oct 9, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, United StatesContact •••6863→•••8100
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, United StatesContact •••6863→•••8100
  • Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, United StatesContact •••6863→•••8100
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) · Commack, United StatesContact •••6863→•••8100
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, United StatesContact •••6863→•••8100
  • Memorial Sloan Kettering Nassau (All Protocol Activities) · Uniondale, United StatesContact •••6863→•••8100
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added, 1 site removed
    Show site
    • Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, United States
    Show 1 removed
    • Memorial Sloan Kettering Westchester (All Protocol Activities) · East White Plains, United States
    Contact Study contact changed: x•••@mskcc.org · •••6863→c•••@mskcc.org · •••8100. See the current contact
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, United StatesContact •••6863→•••8100
    • Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, United StatesContact •••6863→•••8100
    • Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, United StatesContact •••6863→•••8100
    • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) · Commack, United StatesContact •••6863→•••8100
    • Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, United StatesContact •••6863→•••8100
    • Memorial Sloan Kettering Nassau (All Protocol Activities) · Uniondale, United StatesContact •••6863→•••8100
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06717334
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Dec 5, 2024
Start date
Dec 2, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Alexis Chidi, MD, PhD
Contact
chidia1@mskcc.org
212-639-8100
Bernard Park, MD
Contact
646-888-3346
Alexis Chidi, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion